Method for regulating libido

Transcranial electrical stimulation with precise electrode placement and adjustable parameters targets the DLPFC to regulate libido effectively with minimal side effects, addressing the limitations of systemic treatments.

WO2026240683A1PCT designated stage Publication Date: 2026-11-19SMOLINA SVETLANA ALEKSEEVNA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/RU2026/050128
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-06
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing methods for regulating libido, such as pharmacological treatments and transcutaneous electrical nerve stimulation, suffer from systemic side effects and lack targeted regulation of neural networks responsible for sexual motivation, particularly for central nervous system disorders.

Method used

A method using transcranial electrical stimulation (TES) with conductive electrodes, targeting the dorsolateral prefrontal cortex (DLPFC) via precise electrode placement and adjustable current parameters, including anode and cathode coordinates based on the 10-20 electrode system, to stimulate or inhibit neural activity associated with libido.

Benefits of technology

Achieves effective libido regulation with minimal side effects by focusing current on specific brain areas, reducing systemic impacts and drug interactions, suitable for individualized treatment protocols.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000007_0001_TABLE
    Figure IMGF000007_0001_TABLE
  • Figure IMGF000009_0001_TABLE
    Figure IMGF000009_0001_TABLE
  • Figure IMGF000010_0001_TABLE
    Figure IMGF000010_0001_TABLE
Patent Text Reader

Abstract

The invention relates to medicine and can be used for regulating libido. A device for transcranial electrical stimulation (tES) is used. Stimulation is carried out on the dorsolateral prefrontal cortex (DLPFC) of the brain. To increase libido, the left DLPFC is stimulated. To decrease libido, the right DLPFC is stimulated. The method makes it possible to more effectively regulate libido while also reducing side effects on the patient's body.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] A METHOD FOR REGULATING LIBIDO

[0003] The invention relates to the field of non-invasive methods of modulating the cortical activity of the brain by supplying low-intensity electric current through electrodes placed on the head, and can be used in medical practice for the correction of sexual dysfunctions, in psychotherapy, as well as in individual use under the supervision of a specialist [A61N1 / 00, A61N1 / 04],

[0004] A METHOD FOR TREATMENT OF SEXUAL LIBIDO DISORDER IN MEN [RU2345760C1, PUBLISHED 2009-02-10] by using medicinal products is known from the prior art, characterized in that the phosphodiesterase type 5 inhibitor sildenafil citrate is prescribed at a dose of 12.5 mg per dose simultaneously with the antidepressant maprotiline (ludiomil) at a dose of 5.0 mg per dose, once daily for 30 days.

[0005] A disadvantage of this analogue is its pharmacological approach, which involves systemic action on the body, increasing the risk of side effects. Sildenafil (a PDE5 inhibitor) can cause headaches, hypotension, visual disturbances, and gastrointestinal upset. Maprotiline (an antidepressant) is associated with sedation, dry mouth, tachycardia, risk of cardiovascular complications, and withdrawal symptoms. Furthermore, these medications act diffusely, affecting the entire body without targeted regulation of libido through neural networks responsible for sexual motivation. There is also a risk of drug interactions during libido regulation; the combination of sildenafil and maprotiline may interfere with other medications (e.g., nitrates, antiarrhythmics), increasing toxicity.

[0006] The closest prior art is the METHOD OF IMPROVING LIBIDO BY USING ELECTRICITY [US2017348527A1, PUBLISHED 2017-12-07], which includes providing a libido improvement regimen using a transcutaneous electrical nerve stimulation / electronic muscle stimulation (TENS / EMS) device, the regimen includes placing several electrodes of the TENS / EMS device on several areas of the body; electrical stimulation of the body is performed using multiple electrodes, and the regimen is performed at least twice within 24 hours.

[0007] The main technical problem with the prototype is its superficial effect on peripheral nerves and muscles without affecting the central nervous system, which reduces the effectiveness of the method for disorders associated with dysfunction of the central nervous system, and also causes hyperstimulation of peripheral nerves, which increases the side effects of the method.

[0008] The objective of the invention is to eliminate the shortcomings of the prototype.

[0009] The technical result of the invention consists in increasing the effectiveness of libido regulation, as well as in reducing side effects on the patient's body.

[0010] The said technical result of the invention is achieved due to the fact that the method for regulating libido is characterized by the use of a device with conductive electrodes and consists of the following stages:

[0011] - initially, the area of ​​stimulation of the cerebral cortex is determined, while the coordinates of the locations of the anode and cathode are determined depending on the clinical goals;

[0012] - then the anode is placed above the location of the anode;

[0013] - the cathode is placed above the point of the cathode location relative to the anode according to the protocol;

[0014] - then stimulation with electrodes is started, adjusting the current strength and duration of the session in accordance with the protocol parameters.

[0015] In particular, a device with conductive electrodes designed to stimulate the dorsolateral prefrontal cortex of the brain is used.

[0016] In particular, the location of the anode corresponds to the left or right prefrontal cortex.

[0017] In particular, the cathode is placed above the opposite orbitofrontal zone or extracranial relative to the anode, or the cathodes are placed in a circle around the anode.

[0018] Specifically, the cathode is placed extracranially on the shoulder or above the deltoid muscle. Specifically, the anode is surrounded by four cathodes in a ring-shaped configuration.

[0019] Specifically, when surrounding the anode with four cathodes in a ring configuration, the cathodes are placed in the frontopolar-medial position, the caudal position, the medial position, and the lateral position.

[0020] In particular, the electrode placement points correspond to the 10-20 electrode placement system.

[0021] In particular, an electrode action amplitude of 0.1–6 mA is used.

[0022] In particular, the session duration ranges from 5 to 120 minutes.

[0023] Implementation of the invention.

[0024] Transcranial electrical stimulation (TES) is a non-invasive technique for cerebral cortex neurostimulation. It involves applying low-intensity direct or alternating current directly to the scalp, partially penetrating the skull and reaching the brain. Computer modeling studies show that TES can induce significant currents in superficial cortical areas, affecting the patient's neural excitability.

[0025] The electrodes used in TES are connected to a battery-powered device that delivers a weak current (0.1-6 mA) to the electrode sites for a specified duration. In TES, the parameters of current strength, duration (minutes), and direction are critical. Current from the TES stimulating device enters the brain through the anode (+), passes through the cortical and subcortical areas, and exits through the cathode.

[0026] To regulate libido, the dorsolateral prefrontal cortex (DLPFC) is stimulated. To increase libido, the left DLPFC is stimulated. To decrease libido, the right DLPFC is stimulated. DLPFC stimulation using transcranial electrical stimulation is performed according to a protocol tailored to the individual patient's needs and characteristics.

[0027] Initially, the target area of ​​the cerebral cortex is determined, with the coordinates of the anode and cathode points for stimulation to regulate libido determined. Stimulation of the area is performed using a device with conductive electrodes designed to stimulate the dorsolateral prefrontal cortex. A device with electrode positioning according to the international 10-20 coordinate system is used to precisely target the brain areas associated with libido modulation. When stimulating the left dorsolateral prefrontal cortex, the coordinates of the F3 point of the frontal electrode on the left prefrontal cortex are determined. The anode (or active electrode) is positioned over the F3 point, which corresponds to the left prefrontal cortex. The cathode (or return electrode) is placed either over the opposite orbitofrontal cortex (Fp2) or extracranially—for example, on the right shoulder or above the deltoid muscle.Or, for high-precision transcranial stimulation, the anode is surrounded by four cathodes in a ring configuration, with the cathodes positioned in the projections AF3 (frontopolar-medial position), FC3 (caudal position), F1 (medial position), F5 (lateral position).

[0028] The choice of cathode position depends on the goal of the intervention: a cathode placed on the scalp provides a more localized effect, while an extracranial placement minimizes modulation of other cortical areas. Current (direct or alternating) is delivered according to the protocol parameters.

[0029] At the same time, when stimulating the right dorsolateral prefrontal cortex, the coordinates of the right frontal electrode point F4 in the right prefrontal area are determined. The anode is positioned over the F4 point. The cathode position is selected. To focus the stimulation, the cathode is placed over the opposite orbitofrontal zone (the right anterior frontal point Fpl). For extracranial montage, the cathode is placed on the left shoulder or over the deltoid muscle. For stimulation, cathodes are distributed around the anode at the following points: AF4 (frontopolar-medial zone), FC4 (caudal position), F2 (medial position), and F6 (lateral position). Stimulation is initiated, adjusting the current strength and session duration according to the protocol parameters.

[0030] Specifically, electrode amplitudes of 0.1-6 mA are used, with session durations ranging from 5 to 120 minutes and courses lasting from 1 day, depending on the clinical presentation. When using alternating current, a frequency of 1 to 100 Hz is used.

[0031] This targeted stimulation allows for modification of neural activity within the framework of individually tailored therapeutic protocols.

[0032] The claimed invention enables non-invasive libido regulation, while also reducing side effects on the patient's body. The combination of hardware precision, programmable parameters, and digital control makes the method innovative and competitive. This method can be used both in a clinical setting and at home (under specialist supervision). Furthermore, this libido regulation method does not require complex patient preparation or expensive equipment, unlike invasive methods or pharmacotherapy. These advantages make the method promising for implementation in medical practice and individualized treatment.

[0033] use, providing safe, accurate and personalized libido correction.

[0034] Examples of use of the claimed invention.

[0035] Example 1. A 34-year-old female patient presented with a 1.5-year history of decreased libido, which was causing tension in her relationship with her partner. Her hormonal profile (estrogen, testosterone, prolactin) was normal, and there were no chronic illnesses, head injuries, or neurological pathologies. Her medical history included prolonged work-related stress and mild depressive episodes that did not require medication; attempts to correct her condition through psychotherapy and lifestyle modifications were ineffective. The goal of the intervention was to increase libido by stimulating the left dorsolateral prefrontal cortex (DLPFC).

[0036] A 10-20 electrode placement system was used for the procedure, which determined the coordinates of the F3 point, corresponding to the left prefrontal cortex. The anode (active electrode) was positioned over the F3 point, and the cathode (return electrode) was placed extracranially on the right shoulder above the deltoid muscle to generate a targeted current. The current was 2 mA, the session duration was 20 minutes, and the current waveform was constant. The device was activated by gradually increasing the current to the target values. There were no side effects (tingling or itching). After 10 40-minute sessions, three times a week, the patient noted an increase in spontaneous sexual interest, a decrease in anxiety in intimate situations, and an improvement in emotional state, which was associated with the indirect effect of DLPFC stimulation. The effect persisted for three months after completion of the course.

[0037] Example 2. To demonstrate the opposite effect (decreased libido), a 40-year-old man with hypersexuality and compulsive risk-taking behavior was used. He underwent stimulation of the right DLPFC (point F4 in the 10-20 system) with the anode placed above F4 and the cathode placed extracranially on the left shoulder. Parameters: current intensity 1.5 mA, session duration 30 minutes, 12 treatments. The result was a decrease in obsessive sexual desire and an increase in self-control.

[0038] The method is based on data on the functional asymmetry of the brain: stimulation of the left DLPFC enhances motivation and positive emotions, increasing libido, while activation of the right DLPFC suppresses hypersexuality by enhancing inhibitory processes.

[0039] Extracranial placement of the cathode allows focusing the current on the target area, reducing the risk of adverse reactions.

[0040] Example 3. To correct hypersexuality or compulsive sexual behavior, stimulation of the right dorsolateral prefrontal cortex (DLPFC) is used, suppressing neural activity associated with impulsivity. The anode (+) of the tDCS device is fixed over the F4 point (right DLPFC) using the 10-20 system, and the cathodes (-) are placed in a ring configuration around the anode: AF4 (frontopolar-medial position), FC4 (caudal position), F2 (medial position), and F6 (lateral position). The cathode in the AF4 projection additionally emphasizes the effect on the orbitofrontal cortex to enhance impulse control. Sessions are conducted at a current of 6 mA for 120 minutes daily in a course of 10 treatments. This circuit focuses current on the right DLPFC, enhancing its inhibitory function, while modulation of the orbitofrontal area reduces the activity of networks responsible for compulsive behavior.

[0041] Example 4. For the treatment of hypoactive sexual dysfunction, the anode (+) is placed over the F3 point (left DLPFC) using the 10-20 system, and the cathode (-) is placed in the orbitofrontal region. The cathode position at AF3 synchronizes stimulation with the emotional networks of the orbitofrontal cortex. Parameters include a current of 0.1 mA, a session duration of 5 minutes, and a course of 12 treatments performed 3 times per week. Stimulating the orbitofrontal cortex improves emotional regulation by stimulating neuroplasticity in circuits associated with sexual desire.

[0042] The application of this method is not limited to the examples listed above. Additional examples of libido regulation are presented in Table 1.

[0043] Table 1

[0044] Examples of use of the claimed invention

[0045]

[0046] The circular cathode configuration focuses the current on the DLPFC, enhancing local modulation. The orbitofrontal cathode influences emotional and motivational networks (e.g., Fpl / Fp2). The extracranial cathode reduces the risk of side effects by minimizing the impact on other brain areas. The examples cover a variety of clinical scenarios, demonstrating the flexibility of EFT in regulating libido.

[0047] The development and research of treatment options for hypoactive sexual desire disorder in women (Table 2) and excessive sexual desire in men (Table 3) face significant challenges. First, stigma and cultural taboos surrounding sexual health issues lead to underreporting and a lack of focus in research. Second, the complex etiology, including hormonal, neurological, psychological, and social factors, complicates the development of a universal treatment. Moreover, increased libido has long been considered a normal trait and even a sign of health, rather than a disorder, and therefore has not been adequately studied. These factors contribute to the limited and underdeveloped treatment options currently available for sexual desire disorders.

[0048] Table 2 presents the most common treatments for low libido, most of which are not FDA-approved for hypoactive sexual desire disorder, are used off-label, and have a weak evidence base due to a limited number of studies and small sample sizes. All drug mechanisms of action conform to a double-blind model. Results ranged from 18% to 100% efficacy, although each study used different assessment methods and cannot be analyzed objectively. Adverse reaction rates were highest for bremelanotide and lowest for testosterone (excluding psychotherapy). However, testosterone, with its highest efficacy and lowest adverse reaction rates, has safety concerns regarding breast cancer, cardiovascular outcomes, and pregnancy complications.

[0049] Table 2

[0050] Current treatment options for low libido in women.

[0051]

[0052] It's important to note that the treatment landscape for increased libido in men is even less studied than for decreased libido in women. Selective serotonin reuptake inhibitors, such as fluoxetine, have shown some efficacy, but their effects are noted only as side effects in the treatment of depression. Antiandrogens, such as medroxyprogesterone acetate, and LHRH agonists, such as triptorelin, demonstrate high efficacy in sex offenders with comorbid paraphilias, but have not been studied in the general population with increased libido. Psychotherapy has shown a moderate reduction in symptoms after seven weeks, but its effectiveness is based on mixed-gender studies, not groups specifically designed for men. This highlights a significant gap in targeted research and treatment options for men with excessive sexual desire, indicating the need for more inclusive and targeted research to develop effective interventions.Finally, each of the options, except psychotherapy, has different common side effects (Table 3).

[0053] Table 3

[0054] Current treatment options for increased libido in men

[0055]

[0056] A significant challenge in managing both low libido in women and high libido in men is the modest effectiveness of available treatments. For low libido, medications such as Flibanserin (brand name Addyi) and Bremelanotide (brand name Vyleesi), despite FDA approval, show only modest improvements in sexual desire (Table 2). Similarly, treatments for high libido, such as Fluoxetine, Medroxyprogesterone acetate, and Triptorelin, offer higher efficacy but are often repurposed from their original use and therefore lack ESD-specific studies (Table 3).

[0057] Medications for hypoactive sexual desire disorder, such as flibanserin and bremelanotide, can cause dizziness, nausea, and fatigue, which may hinder continued use (Table 2). Furthermore, flibanserin's interaction with alcohol requires significant lifestyle adjustments, requiring women to abstain from alcohol for months during treatment. Regarding excessive sexual desire, despite the aforementioned efficacy rates, the frequency and severity of side effects can significantly impact patients' quality of life, making adherence to these treatments challenging (Table 3).

[0058] The technical result of the invention consists in increasing the effectiveness of libido regulation, as well as in reducing side effects on the patient's body.

[0059] The said technical result of the invention is achieved due to the fact that the method for regulating libido is characterized by the use of a device with conductive electrodes and consists of the following stages:

[0060] - initially, the area of ​​stimulation of the cerebral cortex is determined, while the coordinates of the locations of the anode and cathode are determined depending on the clinical goals;

[0061] - then the anode is placed above the location of the anode;

[0062] - the cathode is placed above the point of the cathode location relative to the anode according to the protocol;

[0063] - then stimulation with electrodes is started, adjusting the current strength and duration of the session in accordance with the protocol parameters.

[0064] Based on this, a comparative analysis of the proposed method with its analogue and prototype was conducted (Table 4). Table 4 demonstrates the key differences between the methods in terms of mechanism of action, efficacy, safety, and other parameters.

[0065] Table 4

[0066] Comparative analysis of the claimed invention, prototype and analogue

[0067]

[0068]

[0069] The claimed method provides targeted action on the neural networks responsible for libido, increasing effectiveness with minimal side effects. The analogue and prototype demonstrate low specificity: the analogue affects the body systemically, while the prototype affects the body superficially.

[0070] This libido-regulating method has the lowest risk of side effects and drug interactions. The analogue is dangerous due to the toxicity of the drug combination and withdrawal symptoms. The prototype may cause discomfort due to hyperstimulation of peripheral nerves.

[0071] The invention allows for tailoring stimulation parameters to the individual patient's needs (for example, selecting a circular cathode configuration or extracranial placement). The analogue and prototype do not take neurophysiological characteristics into account.

[0072] The claimed invention is also suitable for patients with drug-resistant conditions, contraindications to medications, or the need for non-invasive intervention. The analogue and prototype may be temporary solutions, but do not address the root cause of the problem (CNS dysfunction).

[0073] Thus, this method for regulating libido outperforms similar and prototype products due to its high specificity and localized action, minimal systemic side effects, the ability to precisely adjust to individual neurophysiological parameters, and the absence of the risk of drug interactions. This makes the invention the preferred method for long-term libido correction, especially in patients with contraindications to pharmacotherapy or a need for neuromodulation.

[0074] The technical result of the claimed libido regulation method is achieved by defining the stimulation site and electrode coordinates, ensuring precise targeting of the cerebral cortex, increasing effectiveness while minimizing impact on non-target areas. Adjusting the current strength and session duration allows for personalized parameters tailored to the protocol, optimizing stimulation and reducing the risk of side effects.

[0075] Stimulation of the dorsolateral prefrontal cortex (DLPFC) is an area associated with emotional regulation and decision-making. Stimulating it directly influences neural pathways responsible for libido, increasing effectiveness. Taking lateralization into account allows for targeted stimulation of the areas dominant for libido, enhancing results and reducing overstimulation.

[0076] The contralateral orbitofrontal area (CFO) modulate activity in the reward-related area, enhancing the stimulation balance. Extracranial placement or a ring configuration reduces current spread to the brain, reducing side effects.

[0077] The device's international 10-20 electrode positioning system ensures reproducibility and accuracy, reducing electrode placement errors and associated risks. The optimal range (amplitude 0.1–6 mA) provides sufficient stimulation intensity without tissue damage or discomfort, balancing efficacy and safety. Session durations of 5–120 minutes improve tolerability with short sessions (5 minutes) and with longer sessions (120 minutes), they ensure a sustained effect. Time adaptation prevents hyperstimulation, reducing side effects.

[0078] The combination of precise targeting, optimized current parameters, standardized placement methods, and minimization of impact on non-target areas ensures increased effectiveness in libido regulation through targeted modulation of key neural networks and reduced side effects due to localized and controlled action.

Claims

FORMULA 1. A method for regulating libido, characterized by the fact that a device for transcranial electrical stimulation (TES) is used, distinguished in that the area of ​​stimulation of the cerebral cortex is initially determined, while stimulation of the dorsolateral prefrontal cortex of the brain (DLPFC) is carried out, and in order to increase libido, the left DLPFC is stimulated, and in order to decrease libido, the right DLPFC is stimulated.

2. The method according to paragraph 1, characterized in that the cathode is placed above the opposite orbitofrontal zone or extracranial relative to the anode, or the cathodes are placed in a circle around the anode.

3. The method according to paragraph 4, characterized in that the cathode is placed extracranially on the shoulder or above the deltoid muscle.

4. The method according to claim 4, characterized in that the anode is surrounded by four cathodes in a ring configuration.

5. The method according to claim 6, characterized in that when the anode is surrounded by four cathodes in a ring configuration, the cathodes are placed in a frontopolar-medial position, a caudal position, a medial position, and a lateral position.

6. The method according to paragraph 1, characterized in that the points for placing the electrodes correspond to the electrode placement system 10-20.

7. The method according to paragraph 1, characterized in that the amplitude of the electrode action is 0.1–6 mA.

8. The method according to paragraph 1, characterized in that the session duration is from 5 to 120 minutes.